DB
IMMX icon

Dmitry Balyasny’s Immix Biopharma IMMX Stock Holding History

Dmitry Balyasny’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.3M Buy
+417,227
New +$3.87M 0.01% 1446
2026
Q1 		– Sell
-12,854
Closed -$67.2K – 3186
2025
Q4 		$67.2K Buy
+12,854
New +$52.9K ﹤0.01% 2992

Other funds holding IMMX

JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Dmitry Balyasny's IMMX Position: Q2 2026 in Review

Dmitry Balyasny opened a new position in Immix Biopharma (IMMX) in Q2 2026: 417,227 shares worth $4.3M. The stake represents 0.01% of the portfolio and ranks #1446 among its holdings. This is a return to the name: Dmitry Balyasny previously reported a position in IMMX as recently as Q4 2025.

Dmitry Balyasny first reported a position in IMMX in Q4 2025 and has held it in 2 quarters since. 108 funds tracked by Wall St. Rank hold IMMX as of Q2 2026.

  • Dmitry Balyasny held 417,227 shares of Immix Biopharma worth $4.3M as of Q2 2026.
  • Immix Biopharma was a new Dmitry Balyasny position in Q2 2026.
  • Immix Biopharma made up 0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #1446 holding.
  • Dmitry Balyasny first reported a position in Immix Biopharma in Q4 2025 and has held it in 2 quarters since.
  • 108 funds tracked by Wall St. Rank held Immix Biopharma as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.